check_circleStudy Completed

Acute Coronary Syndrome

Bayer Identifier:

17542

ClinicalTrials.gov Identifier:

NCT02673437

EudraCT Number:

Not Available

EU CT Number:

Not Available
SCEM of Rivaroxaban in Acute Coronary Syndrome

Trial purpose

Rivaroxaban is a medicine which reduces the formation of blood clots. Acute coronary syndrome (ACS) comprises a range of disorders, including heart attack and unstable angina, caused by a sudden reduction in blood flow to part of the heart muscle. This study aims to collect information on the use of rivaroxaban and its safety when used by patients for the prevention of atherothrombotic (plaque rupture leading to a blood clot) events following ACS, during the first three months after starting. This study was requested by Epidemiology at Bayer as part of a programme for ACS indication as condition to the MAH. It will last for approximately 3 years and is a national study covering the whole of England and Wales. The study aims to recruit patients who have been prescribed rivaroxaban and antiplatelet therapy and patients who have been prescribed alternative dual antiplatelet therapy for the secondary prevention of atherothrombotic events following ACS. Each patient will only be monitored for the first 12 weeks after hospital admission for ACS. Patients who choose to take part will complete a consent form. The patient's care team will be asked to complete a baseline questionnaire about the patient at the time the medicine is given and a further questionnaire up to 16 weeks later, specifically asking about the patient's experiences whilst on the medication. If anything unusual is reported during the observation period, the care team may be asked to fill out a followup questionnaire. With the patient's consent, the study team will also inform the patient's General Practitioner (GP) of their participation in the study and will ask the GP to complete an abridged questionnaire from the patient's medical records. The study team will analyse and aggregate the data, carefully protecting patient confidentiality, to classify adverse events of interest, in particular bleeding events.

Key Participants Requirements

Sex

All

Age

18 Years
  • - Age 18 years or above
    - Patients newly prescribed rivaroxaban in any combination with standard oral antiplatelet therapy for the indication of secondary prevention in patients after ACS
    - Patients prescribed dual antiplatelet therapy (contextual cohort) for the indication of secondary prevention after ACS
    - Patients have provided signed, informed consent
  • - Patients prescribed with oral anticoagulants including rivaroxaban within 6 months prior to the index date for any indication
    - Patients commenced rivaroxaban between date of market launch (28th October 2014) for the indication of secondary prevention after ACS and study start (18th September 2015)

Trial summary

Enrollment Goal
652
Trial Dates
September 2015 - February 2019
Phase
N/A
Could I Receive a placebo
No
Products
Xarelto (Rivaroxaban, BAY59-7939)
Accepts Healthy Volunteer
No

Primary Outcome

  • Cumulative incidence of major bleeding, overall and stratified by the following bleeding sites: : intracranial, gastrointestinal, urogenital
    Cumulative incidence of major bleeding according to the Thrombolysis In Myocardial Infarction (TIMI) classification of non-coronary artery bypass grafting (non-CABG) Related Bleeding, occurring in the 12 week observation period, overall and stratified by the following bleeding sites: intracranial, gastrointestinal, urogenital.The cumulative incidence will be calculated according to the formula: Total number of new cases during 12 week observation period x 100 / Population initially at risk.
    date_rangeTime Frame:
    During 12 weeks after initiation of treatment with rivaroxaban or alternative antiplatelet therapy
  • Rate of major bleeding, overall and stratified by the following bleeding sites: intracranial, gastrointestinal, urogenital
    date_rangeTime Frame:
    During 12 weeks after initiation of treatment with rivaroxaban or alternative antiplatelet therapy

Trial design

An Observational Post-authorization Safety Specialist Cohort Event Monitoring Study (SCEM) to Monitor the Safety and Utilization of rivaroxaban (XARELTO®) initiated in secondary care for the prevention of atherothrombotic events in patients who have had acute coronary syndrome in England and Wales
Trial Type
Observational
Intervention Type
Other
Trial Purpose
N/A
Allocation
N/A
Blinding
N/A
Assignment
N/A
Trial Arms
N/A

Additional Information

Click here and search for drug information provided by the FDA.Click here and search for information on any recalls, market or product safety alerts by the FDA which might have occurred with this product.